Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Felzartamab (TJ202) in Systemic Lupus Erythematosus
NCT05140824Phase 1Terminated
- Sponsor
- TJ Biopharma
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing TJ202 with Placebo (2 arms). Primary endpoints: Rate of Adverse Events at 113 days, Maximum Plasma Concentration (Cmax) at 113 days and 2 more. Started Dec 2021; status: terminated.
02
Drugs
felzartamab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05140824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140824.